Quest Diagnostics Guides FY Adj EPS $11.05-$11.25, Above Consensus
DGX sits 30% above its 52-week low of $165.777 on elevated volume (2.1× avg).
Summary
Quest Diagnostics issued FY adjusted EPS guidance of $11.05-$11.25, above the consensus estimate of $10.95, with the midpoint of $11.15 implying roughly 8% growth over the prior year's adjusted EPS of $10.32. The company lifted its full-year view on higher second-quarter sales and profit. This follows strong FY25 results and a $1 billion buyback authorization announced in February. The stock is trading near its 52-week high, and the guidance could provide further upside. The next quarterly report will be the first checkpoint against this new range.
At the time of this announcement, DGX was trading at $215.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $23.2B. The 52-week trading range was $165.78 to $219.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.